Medicare Rule Brings More Drug Price Transparency To Part D
Executive SummaryCMS has decided to implement a new definition of "negotiated prices" under the Medicare Part D drug benefit that it believes will bring a new level of transparency to pricing in the program
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.